Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

The deaths of three patients in experimental gene-editing and cell-therapy trials in China, including two children, have raised grave concerns about patient safety, transparency and oversight in the country's clinical-trial system.

The three deaths occurred in separate investigator-initiated trials (IITs), which are studies led by researchers or medical institutions rather than conducted through the conventional drug-development pathway.

The cases have come to light only months after the deaths, prompting US lawmakers to ask the FDA to scrutinise clinical data generated in China more closely.

Three Patients Died In Separate Experimental Trials

One case involved a 6-year-old girl with Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder. She died seven days after receiving an experimental gene-editing treatment at Xinhua Hospital in Shanghai in May 2025.

Reports said the treatment was delivered into the spinal fluid, and the hospital's ethics board later determined that the death was definitely related to the treatment.

A second death involved a boy with Duchenne muscular dystrophy (DMD) who received HuidaGene Therapeutics' experimental CRISPR-based therapy. He died in August 2025 after developing acute respiratory distress syndrome (ARDS) during a severe immune reaction following a high dose of the viral-vector treatment. The company disclosed the death in August 2026 after questions from reporters.

The third case involved a man in his 50s with scleroderma, who died in March 2026 after receiving RiboX Therapeutics' experimental in-vivo CAR-T therapy.

RiboX had announced FDA clearance to begin testing the treatment in the US shortly before the death became public.

Also read: Early Trial Examines A One-Time Treatment That Could Replace Statins To Manage High Cholesterol: Study

Why Gene Therapy Can Trigger Serious Reactions?

High doses can further increase this risk. In the HuidaGene case, the child developed ARDS during what the company described as a severe immune reaction. Such reactions can cause widespread inflammation and damage organs, making them potentially life-threatening.

Gene editing also carries another category of risk: the treatment is intended to alter genetic material, so researchers must carefully assess whether editing occurs only at the intended target and whether the delivery system itself creates additional risks.

Also read: UK Plans £22 Million Mini Human Organs Project To Cut Down Animal Testing In Science

Bigger Concern Is Trial Oversight

The deaths have attracted particular attention because they occurred in trials initiated by investigator, which have historically offered researchers a faster route to testing experimental therapies.

Unlike conventional clinical trials, these studies have operated under a different regulatory framework in China. Reports have raised concerns about whether independent safety monitoring was adequate in some cases.

For example, the HuidaGene trial did not have an independent data safety monitoring board, according to reporting by STAT. The study enrolled four boys, and the child who died was the fourth participant to receive treatment and received the highest dose administered in the trial.

US Lawmakers Are Calling For Greater Scrutiny

The cases have prompted Representatives John Moolenaar and Ben Cline to ask the FDA to stop accepting Chinese clinical-trial data for US drug applications unless the agency has recently inspected the trial site.

In a letter to Acting FDA Commissioner Kyle Diamantas, the lawmakers said, “American families deserve confidence that the treatments approved in our country are supported by data produced with rigor, ethics, and accountability.”

At least 1 in 4 former NFL players who died between 2016 and 2021 had chronic traumatic encephalopathy (CTE), according to a new study published in the BMJ. Researchers say the figure may be a conservative estimate, raising concerns about the long-term effects of repeated head impacts in American football.

The study examined 878 former NFL players who died during the six-year period. Of them, 235 had donated their brains for research, and 215, or 91.5%, were found to have CTE.

As brain donation was not available for everyone who died, researchers calculated that at least 24.5% of the entire group had CTE. Researchers say the actual number could be substantially higher.

What Is CTE?

Repeated head impacts can cause abnormal accumulation of tau protein in the brain. Over time, these changes can damage and kill brain cells, particularly in areas involved in memory, thinking, mood and behaviour.

The damage is not always caused by one dramatic concussion. Researchers focus on the cumulative burden of repeated head impacts, including hits that may not cause obvious concussion symptoms.

Also read: US Measles Outbreak: Pennsylvania Reports First Deaths Of 2026 As Trump Pushes Back On Vaccines

Brain Damage Can Build Up Over Years

CTE can be associated with symptoms including memory problems, confusion, impaired judgement, depression, anxiety, aggression and difficulties controlling impulses.

The new study also found a strong relationship between more advanced CTE and dementia. Among players with the most severe, Stage IV disease, dementia was particularly common.

Dr Daniel Daneshvar, a neurologist at Mass General Brigham and lead author of the study, said, "Former NFL players had about a fourfold higher risk of dying from neurodegenerative disease compared with the general population."

Also read: Delhi H1N1 Cases Cross 2,300: No New Strain, Flu Mostly Self-Limiting, Says ICMR Chief

The Risk May Begin Before The NFL

One important finding is that the brain injury associated with CTE does not necessarily begin during an NFL career.

Players may accumulate thousands of head impacts during childhood, high school and college football, before ever reaching the professional level.

Researchers therefore say prevention needs to focus on reducing repetitive head impacts throughout a player's sporting career, rather than concentrating only on professional football.

This also explains why researchers distinguish between concussions and repetitive head impacts. A player can experience numerous hits without being diagnosed with a concussion, yet the cumulative exposure may still have a lasting impact in long term.

Can CTE Be Detected Or Treated While Someone Is Alive?

One of the biggest challenges is detecting CTE while someone is alive. There is currently no definitive test that can diagnose CTE during life and no cure that can reverse the underlying brain changes.

Researchers are studying biomarkers and brain-imaging techniques that could eventually make diagnosis possible without an autopsy. The treatment focuses on managing symptoms like depression, sleep problems, headaches, cognitive difficulties and behavioural changes.

Country music legend Dolly Parton died at 80 after a brief battle with cancer, her representatives confirmed on Tuesday, revealing that the singer had been dealing with the disease before her death. The type of cancer has not been disclosed.

According to a statement from her representatives, Parton died at Vanderbilt-Ingram Cancer Center in Nashville, surrounded by loved ones. Her nephew, Bryan Seaver, announced her death earlier on Tuesday.

Her representatives said she had “bravely” faced the illness but did not provide further details about when she was diagnosed or what treatment she received.

About Dolly Parton’s Cancer

Not much has been publicly revealed about Dolly Parton’s cancer. Her representatives have only described it as a brief battle with cancer, and no specific cancer type, stage or treatment has been announced. It would therefore be premature to speculate about what type of cancer she had or what caused her death.

Reports in recent months had indicated that Parton was dealing with several health problems and had withdrawn herself from some public appearances. She had also cancelled a planned Las Vegas residency earlier this year because of health concerns. Despite those health struggles, Parton continued to speak publicly about wanting to work and pursue new projects.

Also read: US Measles Outbreak: Pennsylvania Reports First Deaths Of 2026 As Trump Pushes Back On Vaccines

Parton Was Vocal About Some Health Issues

Parton had previously spoken about health challenges, although her representatives' latest statement provides the first confirmation of a cancer diagnosis.

Recent reports said she had experienced immune and digestive problems and kidney stones, while she also acknowledged that she had neglected some aspects of her health while caring for her late husband, Carl Dean, who died in 2025.

Her death has now brought renewed attention to the importance of recognising persistent health changes, particularly in older adults.

Some Cancers May Progress Rapidly

Also read: Florida Sees 23 Locally Acquired Dengue Cases This Year: Why A Tropical Virus Is Spreading In The US?

More than 100 types of cancer can develop in different organs, and their behaviour can vary dramatically.

Some cancers grow slowly and may remain manageable for years, while others can progress rapidly or spread to other parts of the body before they are detected.

The symptoms of some cancers may also be subtle. Depending on the cancer, warning signs may include unexplained weight loss, persistent fatigue, unusual bleeding, a lasting change in bowel or bladder habits, persistent pain, a new lump or changes in the skin.

However, these symptoms can also be caused by many non-cancerous conditions. Their presence does not automatically mean someone has cancer. Therefore, it is important to seek medical help if someone is facing any of these symptoms.

Philanthropic Work

Parton's connection with healthcare extended well beyond her personal health. In 2020, she donated $1 million to Vanderbilt University Medical Center to support COVID-19 research. Her contribution helped fund research that became part of the work leading to Moderna's COVID-19 vaccine.

She also supported healthcare and community initiatives in her native Tennessee. Parton died after a career spanning nearly six decades, leaving behind an extraordinary musical and philanthropic legacy. Her representatives said she spent her life bringing “joy, laughter, hope and integrity” to others.